-
We are completely geared up for the launch of ayurvedic products, personal care products by 2021-2022, MP Ramachandran, Chairman & Managing Director of Jyothy Laboratories said.
-
In an interview to CNBC-TV18, K Ullas Kamath, Joint MD & CFO of Jyothy Laboratories spoke about the latest happenings in his company and the sector.
-
In an interview to CNBC-TV18, K Ullas Kamath, Joint MD & CFO of Jyothy Laboratories spoke about the latest happenings in his company and sector.
-
In an interview to CNBC-TV18, K Ullas Kamath, Joint MD & CFO of Jyothy Laboratories spoke briefly about goods and services tax (GST) and the latest happenings in the company.
-
Price at which stake can be bought will be decided mutually and it cannot be less than Sebi guidelines, says K Ullas Kamath, Joint MD and CFO of Jyothy Laboratories.
-
Speaking to CNBC-TV18, Raghunandan says that rural demand will be much better in 2016.
-
S Raghunandan, whole-time director and CEO of Jyothy Laboratories says Ujala, the company‘s lead brand in the fabric whitener segment enjoys a dominant position with 78 percent market share.
-
In an interview to CNBC-TV18, K Ullas Kamath, joint managing director & chief financial officer, Jyothy Laboratories, shares his views on the company's likely performance in Q3 and the impact the Chennai floods will have on the same.
-
In an interview with CNBC-TV18, Ullas Kamath, Joint MD and CFO of Jyothy Laboratories said the rural and urban demand are improving with a fall in commodity prices and low inflation numbers.
-
The company is also aiming for a top line growth of 18-20 percent for FY15.
-
We expect 15-20 percent EBITDA in laundry service eventually, Ullas Kamath, joint managing director of Jyothy Laboratories said.
-
Speaking to CNBC-TV18, Ullas Kamath, joint managing director, Jyothy Labs says the company now has a was chest of Rs 250 crore which the pharma company will use to expand inorganically.
-
Ullas Kamath, Joint Managing Director says the company will stick to its guidance of 20-25 percent topline growth and 14-15 percent EBITDA for full fiscal year.
-
According to Ullas Kamath, the company is seeing robust volume growth in the semi urban and rural and will hold on to its guidance of 20 percent upward on the topline growth for FY14.
-
For Jyothy Labs they have a fantasttic team in place, products in place, integration too is complete and good cash flows too are coming in, therefore they are now ready to do their best, adds Ullas Kamath of Jyothy Laboratories.
-
K Ullas Kamath, deputy managing director of Jyothy Laboratories sees 25% top-line growth and 25% bottom-line growth in FY13.
-
Jyothy Laboratories said that the integration of the companies is almost complete. However, the merger process is likely to take another six to eight months and it will be effective from April 1, 2012
-
K Ullas Kamath, deputy managing director of Jyothy Laboratories says, he expects minimum of 20-25% growth in Henkel’s business going forward.
-
Mumbai-based Jyothy Laboratories has acquired a 14.9% stake in Henkel India from Tamil Nadu Petro Products for Rs 60.73 crore in an all-cash deal.
-
In an interview with CNBC-TV18, K Ulhas Kamath, Deputy MD, Jyothy Labs spoke about the company's acquisition plans and the way forward.
-
Ulhas Kamath, Deputy Managing Director of Jyothy Laboratories, told CNBC-TV18 that contrary to the market speculations, the company is not looking at acquiring the Indian assets of Henkel AG. “We have our own plans on organic growth and we are not looking at Henkel as an asset in our portfolio,” he asserts.
